CJT-L28

CJT-L28 is an undisclosed pharmaceutical candidate being developed by Crossject for use in emergency or crisis situations within the fields of neurology and psychiatry. The product utilizes Crossject's proprietary ZENEO® technology, a needle-free autoinjector designed for rapid, intramuscular drug delivery. CJT-L28 is being developed via the FDA's 505(b)(2) regulatory pathway, which typically applies to new formulations or delivery formats of previously approved active pharmaceutical ingredients. As of 2024, the specific molecule and biological target remain undisclosed, with a projected target launch date of 2030.